

Original Paper

Smartphone-Based Digital Eczema Education Program for Atopic Dermatitis in Children Aged 0 to 6 Years: Multicenter, Randomized, Parallel Controlled Clinical Study

Huan Yang^{1*}, MD, PhD; Hong Shu^{2*}, MD; Liu-hui Wang^{3*}, MD; Ping Li^{4*}, MD, PhD; Yun-ling Li⁵, MD; Qin-feng Li⁶, MD; Xiu-ping Han⁷, MD; Jing Tian⁸, MD; Jing Chang⁹, MD; Hua Qian¹⁰, MD, PhD; Jing-ping Chen¹¹, MM; Xin-qiang Ding¹², MD; Pan-qian Wu², MD; Li-min Dou³, MD; Zhen Luo⁴, MD; Wei Li⁵, MM; Yang-yang Lin⁶, MD; Lin Li⁷, MD; Shu-zhen Yue⁹, MD; Yang Gu¹⁰, MM; Li Yang¹¹, MD; Xiao-hong Sun¹², MD; Xiao-yan Luo^{1*}, MD, PhD; Lin Ma^{8*}, MD, PhD; Hua Wang^{1*}, MD, PhD

¹Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China

²Department of Dermatology, Kunming Children's Hospital, Kunming, China

³Department of Dermatology, Children's Hospital of Fudan University, Shanghai, China

⁴Department of Dermatology, Shenzhen Children's Hospital, Shenzhen, China

⁵Department of Dermatology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center of Child Health, Hangzhou, China

⁶Department of Dermatology, Tianjin Children's Hospital, Tianjin, China

⁷Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang, China

⁸Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China

⁹Department of Dermatology, Hunan Children's Hospital, Changsha, China

¹⁰Department of Dermatology, Children's Hospital of Soochow University, Suzhou, China

¹¹Department of Dermatology, Guangzhou Woman and Children's Medical Center, Guangzhou, China

¹²Department of Dermatology, Xi'an Children's Hospital, Xi'an, China

*these authors contributed equally

Corresponding Author:

Hua Wang, MD, PhD

Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders

Ministry of Education Key Laboratory of Child Development and Disorders

NO.136 Zhongshan 2nd Road, Yuzhong District

Chongqing 400014

China

Phone: +86-23-63638830

Email: huawang@hospital.cqmu.edu.cn

Abstract

Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that affects approximately 10% to 20% of children, imposing substantial health and economic burdens. Although education for patients and caregivers is acknowledged as a crucial element in the management of AD, conventional approaches, such as workshops or in-person consultations, are often resource intensive and face challenges related to scalability, personalization, and relapse prevention. Digital tools present promising alternatives; however, empirical evidence supporting their effectiveness in young children is currently limited.

Objective: This study aimed to evaluate whether a smartphone-based patient-caregiver educational program could reduce relapse rates in children aged 0 to 6 years with moderate-to-severe AD, compared with conventional outpatient consultation alone.

Methods: In this multicenter, randomized, parallel-controlled trial, 615 children were enrolled across 12 tertiary pediatric dermatology centers in China and randomized (1:1) to receive either a smartphone-based digital education program with standard care (intervention group) or conventional face-to-face consultation only (control group). The 12-week digital

program, delivered via the WeChat-based *Skin Care E-Station* platform, included structured multimedia modules, interactive educational materials, and a dynamic electronic action plan tailored to the child's age and disease stage. The primary endpoint was the 12-week relapse rate after the acute treatment phase. The secondary endpoints included changes in disease severity (Scoring Atopic Dermatitis, Peak Pruritus Numerical Rating Scale, and Patient-Oriented Eczema Measure) and quality of life (Children's Dermatology Life Quality Index or Infant's Dermatitis Quality of Life Index and Dermatitis Family Impact) up to 52 weeks.

Results: Among 615 randomized participants (mean age 3.3, SD 1.7 y; n=317, 51.5% male), relapse at 12 weeks occurred significantly less frequently in the digital education group than in the control group (16.6% vs 24.0%; relative risk 0.69, 95% CI 0.50-0.96; $P=.02$). Kaplan-Meier analysis showed superior relapse-free survival over the first 100 days (hazard ratio 0.688, 95% CI 0.490-0.966; $P=.03$). Differences in relapse rates beyond 12 weeks and in secondary outcomes were not statistically significant. Engagement tracking indicated high adherence to the intervention, with 58.0% of caregivers maintaining regular weekly use of the digital platform.

Conclusions: A structured smartphone-based patient-caregiver educational intervention significantly reduced short-term relapse risk among young children with moderate-to-severe AD, likely through improved caregiver recognition and early management of disease flares. Although effects diminished beyond 12 weeks, this approach demonstrates that scalable digital education is a feasible and effective adjunct to standard care in pediatric AD. Future research should focus on sustaining engagement, optimizing long-term reinforcement, and assessing cost-effectiveness in diverse caregiver populations.

Trial Registration: Chinese Clinical Trial Registry ChiCTR2000031474; <https://www.chictr.org.cn/showproj.html?proj=32400>

J Med Internet Res 2026;28:e79559; doi: [10.2196/79559](https://doi.org/10.2196/79559)

Keywords: atopic dermatitis; digital education; smartphone-based intervention; caregiver engagement; relapse prevention; randomized controlled trial; pediatric dermatology; telemedicine portal; self-management; multicenter study

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense pruritus and eczematous lesions, accompanied by episodic exacerbations and persistent skin symptoms [1]. AD is recognized as a global health concern, affecting up to 20% of children and approximately 3% of adults worldwide [2]. In China, the prevalence of AD stands at approximately 30.48% among infants aged <1 year [3] and 12.94% among children aged 1 to 7 years [4], imposing substantial economic and public health burdens [5, 6]. The recurrent nature of AD presents unique challenges, as patients often experience periods of exacerbation interspersed with phases of relative remission [1]. This cyclical pattern highlights the necessity for effective management strategies that not only address current symptoms but also equip patients and their caregivers with the knowledge and skills to prevent future recurrences [7].

Patient-caregiver education has emerged as a pivotal component of AD management, as highlighted in many international guidelines [8-12]. It is important to note that for pediatric AD populations, the primary focus of education is often on parents and caregivers, especially for infants and young children. As children grow older and their understanding develops, education can be progressively tailored and delivered directly to the patients themselves, in an age-appropriate manner. Providing patients and their caregivers with comprehensive information about the condition, its triggers, management strategies, and the importance of adherence to treatment regimens can empower them to take an active role in their own care [13]. Studies have shown that patients and families who receive structured educational programs are more likely to engage in treatment and preventive measures,

leading to better overall outcomes and reduced disease severity, as evidenced by metrics such as Scoring Atopic Dermatitis (SCORAD) and Children's Dermatology Life Quality Index (CDLQI) [14]. Furthermore, patient-caregiver education may contribute to interrupting the "atopic march" toward comorbidities such as allergic rhinitis [15]. Despite the recognized importance of education, gaps remain in the current approaches used to educate patients with AD and their caregivers. Existing educational models, including workshops [16-19], eczema schools [20-23], and printed materials [19, 24-26], are resource intensive, lack personalization, or fail to sufficiently address the specific concerns and experiences of patients and caregivers. As a result, patients and their families may feel overwhelmed or unsupported in managing their condition, leading to suboptimal adherence and an increased risk of recurrent flares [27,28]. In addition, prior investigations have predominantly focused on the short-term efficacy of educational interventions, whereas the impact of education on the prevention of AD relapse remains considerably underexplored [29].

The COVID-19 pandemic has instigated a paradigm shift toward digital health [30], resulting in an increased willingness among patients with AD and caregivers to use digital tools. Mobile platforms that integrate multimedia content, such as videos, interactive texts, and illustrated narratives, offer advantages in accessibility, engagement, and personalized learning experiences. These platforms theoretically address traditional limitations by providing scalable and adaptive interventions. However, empirical evidence supporting such innovations remains limited, particularly in children with AD.

In this multicenter, randomized controlled trial (RCT), we aim to assess the efficacy of a smartphone-based digital

educational program in comparison to conventional outpatient consultation alone on the relapse rates of AD. By leveraging high smartphone penetration, this trial seeks to develop a more effective educational intervention that will ultimately reduce the burden of AD.

Methods

Study Design

This multicenter, parallel RCT (ChiCTR2000031474) was conducted within the pediatric dermatology departments of 12 tertiary public hospitals across China, including locations in Chongqing, Beijing, Liaoning, Shanghai, Shenzhen, Zhejiang, Hunan, Xi'an, Suzhou, Tianjin, Kunming, and Guangdong ([Multimedia Appendix 1](#)). The trial adhered to the CONSORT (Consolidated Standards of Reporting Trials) reporting guidelines ([Checklist 1](#)).

Participants

Children aged 0 to 6 years diagnosed with AD according to the American Academy of Dermatology Consensus criteria were eligible for inclusion if they presented with moderate-to-severe AD (SCORAD ≥ 25 ; Investigator's Global Assessment [IGA] ≥ 3) and had caregivers proficient in reading Chinese characters and using a smartphone. All participants were recruited through in-person clinical visits. Exclusion criteria included children with severe infections, psychiatric disorders, primary or secondary immune deficiencies, malignancies, or other medical conditions that significantly impair quality of life. Additionally, caregivers with mental disorders or cognitive impairment, prior participation in any patient-caregiver education program, and severe AD requiring systemic treatment were excluded.

Most caregivers were the patients' parents, and a minority were grandparents. All caregivers lived in the same household as the child, as families of "left-behind children," defined as children who remain in their hometowns in China for more than 6 months under the care of grandparents or other relatives while both parents migrate to urban areas for work, were excluded to avoid potential confounding due to social and environmental separation. Caregiver demographic details (eg, age and education level) were not collected, as the original study design focused on patient-level outcomes.

Randomization and Blinding

Eligible patients were randomly assigned in a 1:1 ratio to either the intervention group (smartphone-based digital education program plus standard care) or the control group (conventional outpatient consultation only). Randomization was conducted using a computer-generated number table with a block size of 4. The digital educational intervention protocol was developed and administered through a secure

cloud-based platform operated by an independent clinical research organization (CRO) not involved in trial execution. This third-party CRO was responsible for maintaining the randomization database, delivering standardized digital educational content (including interactive modules, video tutorials, and self-assessment tools), and monitoring intervention adherence by automated adherence reminders (SMS text messaging or telephone) and digital footprint tracking (platform logins and content interaction time). Crucially, the CRO had no involvement in participant recruitment, clinical management, or outcome evaluation processes to ensure blinding integrity.

Intervention and Procedures

Overview


Before trial initiation, all participating dermatologists completed a 4-hour standardized training program on evidence-based patient-caregiver education.

At baseline enrollment, all patients were provided with a 1-page education leaflet ([Multimedia Appendix 2](#)) and completed disease severity assessments along with standardized questionnaires. Subsequently, participants entered a 2-week acute-phase treatment period, conducted strictly according to established clinical guidelines [10-12]. The acute-phase regimen included once-daily topical pharmacotherapy, 0.05% desonide or 0.1% hydrocortisone butyrate for those aged 0 to 2 years and 0.1% mometasone furoate for children older than 2 years, combined with nonpharmacological care. The nonpharmacological regimen consisted of twice-daily application of a ceramide-dominant emollient and daily bathing restricted to fewer than 10 minutes at water temperatures below 38°C. Patient status was reassessed every 14 (SD 2) days using the IGA. Patients achieving an IGA score ≤ 2 were advanced to the maintenance phase.

Digital Education Intervention

Upon entering the maintenance phase, participants in the intervention group were instructed to receive the digital health education program via the WeChat (Tencent Holdings Ltd)-based online platform "Skin Care E-Station" ([Figure 1](#)). This digital portal contained all educational components and could be accessed by scanning a QR code, without requiring any additional software installation. A procedural overview of patient enrollment and identity verification within the platform is provided in [Multimedia Appendix 3](#). As WeChat is a widely used multifunctional communication, social, and payment application in China, this ensured high accessibility and user engagement. The platform consisted of three core components: (1) structured multimedia educational modules, (2) automated follow-up reminders, and (3) emergency response protocols for disease exacerbations.

Figure 1. Skin Care E-Station workflow. Participants in the digital education group accessed the clinical research organization–managed smartphone platform, receiving thrice-weekly education action plans (Mondays/Wednesdays/Fridays) for 12 wk alongside 54 structured multimedia modules (text/images/video/animations) distributed evenly throughout the 52-week program. The content covered AD pathophysiology, care routines, treatments, lifestyle, and mental health support, with real-time clinician access via an encrypted telemedicine portal (<8 h response) during flares. The illustration was created on the FIGDRAW 2.0 platform. AD: atopic dermatitis.



The digital education comprised 2 major elements. The first element was an electronic education action plan (EAP). Each participant in the intervention group received a digital, dynamically tailored EAP ([Multimedia Appendix 4](#)), customized according to the child's age group (1-2 y vs 2-6 y) and disease phase (acute flare vs maintenance). The EAP provided phase-specific guidance on bathing routines, emollient application, medication use, self-assessment of disease severity, and access to emergency consultations. The EAP was automatically delivered 3 times per week (Mondays, Wednesdays, and Fridays) for 12 consecutive weeks. The second element was structured multimedia educational modules. The core educational curriculum was collaboratively developed by the 12 participating centers, integrating an analysis of the most frequent caregiver concerns and key clinician recommendations from routine practice, supplemented by insights and experiences from other research teams [17-24]. This content was organized into 6 domains (AD pathophysiology, patient behaviors, lifestyle modifications, daily care, treatment strategies, and mental health support) and subsequently produced by an independent third-party company into 54 structured multimedia modules. These modules were delivered in formats tailored for children aged 0 to 6 years and their caregivers, including illustrated text (sample in [Multimedia Appendix 5](#)), images (sample in [Multimedia Appendix 6](#)), videos (sample in [Multimedia Appendix 7](#)), and animated stories (sample in [Multimedia Appendix 8](#)). The intervention group did not receive any additional systematic face-to-face patient education during scheduled follow-up visits or at unscheduled clinical encounters.

Control Group

Participants in the control group received only conventional education, consisting of a 15-minute face-to-face counseling session conducted at each scheduled follow-up visit. They were also provided with access to the "Skin Care E-Station" platform for noneducational purposes, including data collection and automated follow-up reminders, but did not receive any educational content, such as the EAP or structured multimedia modules.

Maintenance-Phase Treatment Regimen

Both the intervention and control groups received identical pharmacological treatments during the maintenance phase. In the 0 to 2 years age group, maintenance therapy comprised twice-weekly application of 0.05% desonide or 0.1% hydrocortisone butyrate cream, together with daily emollient use. In children aged >2 years, maintenance consisted of twice-weekly application of 0.03% tacrolimus ointment, alongside regular emollient therapy.

Assessments and Outcomes

Assessments were conducted at 4, 8, 12, 24, 36, and 52 weeks following randomization. Disease severity was evaluated using SCORAD, IGA, Peak Pruritus Numerical Rating Scale (PP-NRS) for pruritus, and the Patient-Oriented Eczema Measure (POEM). Quality of life was assessed using the Dermatitis Family Impact (DFI), the CDLQI, and the Infant's Dermatitis Quality of Life Index (IDQOL). The assessments were completed as follows: If the child was able to attend an in-person visit, the evaluations were performed by physicians not involved in the educational intervention; if not, caregivers uploaded photos and completed the PP-NRS,

POEM, Quality of Life (QoL) questionnaires, and SCORAD self-assessment ([Multimedia Appendix 9](#)) on the platform. Subsequently, physicians not involved in the educational intervention performed the IGA and SCORAD assessments based on the uploaded photos and the SCORAD self-assessment form.

In addition, the timing of each relapse was meticulously recorded. Relapse was defined as an increase of ≥ 10 points in the SCORAD score relative to the value recorded at the conclusion of the 2-week acute-phase treatment. The primary endpoint was the relapse rate at 12 weeks. The secondary endpoints included the changes in disease severity scores (SCORAD, PP-NRS, and POEM) and quality of life scores (CDLQI/IDQOL and DFI) from week 2 (end of the acute-phase treatment) to weeks 4, 8, 12, 24, 36, and 52 in both groups.

Statistical Analyses

Statistical analyses were performed using R (version 4.0.5; R Foundation for Statistical Computing). Sample size estimation was based on an expected 12-week relapse rate of 30% in the digital education group and 45% in the control group, which were derived from a multicenter randomized controlled clinical study on long-term intermittent maintenance therapy for children with AD conducted in China [31]. Assuming a 1:1 allocation ratio and a 30% expected dropout rate, an empirically supported adjustment commonly recommended in sample size estimation to maintain statistical power for both completer and intention-to-treat (ITT) analyses [32], a minimum of 229 patients per group was required to achieve 80% power with an α level of .05.

All analyses followed the ITT principle, which includes all randomized participants in the groups to which they were originally assigned. This approach maintains the integrity of randomization and provides a conservative estimate of treatment effectiveness in real-world clinical settings. To address missing data, multiple imputation by chained equations (MICEs) was performed under the assumption that the data were missing at random. Missing at random implies that the probability of missingness depends only on observed data and not on unobserved data. MICEs generate multiple plausible values for missing data based on observed variables, and we used 5 imputations ($m=10$) to account for uncertainty. The results from the imputed datasets were combined according to Rubin's rules. Normality of continuous variables was evaluated using the Kolmogorov-Smirnov test, a nonparametric test that compares the empirical distribution of the data with a theoretical normal distribution to assess deviations from normality. Data with normal distributions were presented as mean (SD) and compared using independent t tests. Nonnormally distributed data were presented as median (IQR) and analyzed using the Mann-Whitney test.

For the primary outcome, the 12-week relapse rate was compared between groups using the chi-square test. Time to relapse over 100 days was visualized using Kaplan-Meier curves and compared using the log-rank test.

Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs, both unadjusted and adjusted for age and sex.

For continuous outcomes repeatedly measured over time (SCORAD, POEM, PP-NRS, IDQOL/CDLQI, and DFI), population-averaged generalized estimating equations were used with a Gaussian family, identity link, exchangeable correlation structure, and robust SEs to account for within-subject correlations. Each model was adjusted for baseline score, age, and sex. Missing data in these repeated measures were handled using MICEs (10 imputations), with final estimates combined using Rubin's rules.

A 2-sided P value of .04 was considered statistically significant.

Ethical Considerations


This study was reviewed and approved by the Medical Research Ethics Committee of the Children's Hospital of Chongqing Medical University (approval No. 2019-44-1). Written informed consent was obtained from all participants and their guardians before their involvement in the study. All collected data were deidentified to protect participant privacy and confidentiality. No compensation was provided to the participants.

Results

Participant Flow and Cohort Characteristics

The multicenter trial was conducted across 12 tertiary dermatology centers in China from July 2020 to March 2021, with a detailed CONSORT flow presented in [Figure 2](#). Of 980 screened children with moderate-to-severe AD, 615 (62.8%) met inclusion criteria and were subsequently randomized into the digital education group ($n=307$, 49.9%) and the control group ($n=308$, 50.1%). Significant differences in attrition rates were observed at 12 weeks, with 20.2% (62/307) in the digital education group and 27.6% (85/308) in the control group (95% CI 0.66-0.98; $\chi^2_1=4.1$; $P=.04$). Ultimately, 48.62% (299/615) completed the 52-week follow-up, comprising the per-protocol population: digital education ($n=148$, 24.1%) and control ($n=151$, 24.6%).

Baseline characteristics demonstrated adequate randomization balance ([Table 1](#)), with no significant differences observed in gender distribution (men: 52.1% vs 50.8%; $P=.74$), mean age (3.2, SD 1.8, vs 3.4, SD 1.7 y; $P=.21$), or disease severity measures, including SCORAD (49 [40, 59] vs 47.5 [37, 55]; $P=.29$), PP-NRS (6 [6, 8] vs 6 [5, 8]; $P=.31$) and POEM (15 [11, 20] vs 15 [11, 19]; $P=.50$). Similarly, no significant differences were noted in quality-of-life measures, including DFI (9 [4, 16] vs 10 [5, 16]; $P=.77$) and QoL scores (13 [11, 15] vs 14 [11, 16]; $P=.11$). Quality of life was assessed using the CDLQI for children and IDQOL for infants.

Figure 2. CONSORT diagram of the randomization and follow-up of the study participants. AD: atopic dermatitis.**Table 1.** The details of clinical characteristics of randomized patients. QoL was assessed using the Children's Dermatology Life Quality Index for children and the Infants' Dermatitis Quality of Life Index for infants.

Characteristic	Digital education (n=307)	Control (n=308)	P value
Gender, male (%)	52.1	50.8	.74
Age (y), mean (SD)	3.2 (1.8)	3.4 (1.7)	.21
SCORAD ^a , median (Q1 ^b , Q3 ^c)	49 (40, 59)	47.5 (37, 55)	.29
PP-NRS ^d , median (Q1, Q3)	6 (6, 8)	6 (5, 8)	.31
DFI ^e , median (Q1, Q3)	9 (4, 16)	10 (5, 16)	.77
POEM ^f , median (Q1, Q3)	15 (11, 20)	15 (11, 19)	.50
QoL ^g , median (Q1, Q3)	13 (11, 15)	14 (11, 16)	.11

^aSCORAD: Scoring Atopic Dermatitis.^bQ1: the first quartile.^cQ3: the third quartile.^dPP-NRS: Peak-Pruritus Numerical Rating Scale.^eDFI: Dermatitis Family Impact.^fPOEM: Patient-Oriented Eczema Measure.^gQoL: quality of life.

Intervention Adherence and Participant Engagement

Intervention adherence, as measured by digital footprint tracking, demonstrated that 58.0% (178/307) of participants

in the digital education group maintained regular engagement, averaging 1.64 (SD 0.38) sessions per week, and 26.7% (82/307) accessed the expedited physician consultation portals during disease flares. In the control arm, clinic attendance at the 52-week follow-up was 49.0% (151/308).

The 9.0% absolute difference in adherence between groups was statistically significant ($Z=2.3$, 95%CI 1.15%-16.85%; $P=.03$).


Primary Outcome: Relapse Prevention

The ITT analysis revealed a significant reduction in relapse rates in the digital education group at 12 weeks (16.6% [51/307] vs 24.0% [74/308]; relative risk [RR] 0.69, 95% CI 0.50-0.96; $\chi^2_1=5.1$; $P=.02$). However, there was no statistically significant difference between the 2 groups at other time points: 4 weeks (8.79% vs 12.99%; RR 0.68, 95% CI 0.42-1.09; $\chi^2_1=2.8$; $P=.10$), 8 weeks (15.64% vs 21.43%; RR

0.73, 95% CI 0.52-1.02; $\chi^2_1=3.4$; $P=.07$), 24 weeks (21.82% vs 27.60%; RR 0.79, 95% CI 0.60-1.04; $\chi^2_1=2.8$; $P=.10$), 36 weeks (23.13% vs 29.22%; RR 0.79, 95% CI 0.60-1.03; $\chi^2_1=3.0$; $P=.09$), and 52 weeks (24.76% vs 31.17%; RR 0.79, 95% CI 0.62-1.03, $\chi^2_1=3.1$; $P=.08$).

Kaplan-Meier analysis (100-d follow-up) further supported the 12-week finding, showing a significant difference in relapse risk between groups (HR] 0.688, 95% CI 0.490-0.966; $\chi^2_1=4.7$; $P=.03$; Figure 3). In a Cox proportional hazards model adjusting for age and sex, the HR remained significant (adjusted HR 0.665, 95% CI 0.469-0.943; $P=.02$).

Figure 3. Kaplan-Meier estimates of relapse. Hundred-day relapse-free survival curves in the intention-to-treat set analysis.



Secondary Outcomes: Disease Severity Trajectories

Changes in disease severity scores (including SCORAD, PP-NRS, and POEM) and QoL scores (IDQOL/CDLQI and DFI) from week 2 (the end of the acute treatment phase) were compared between the 2 groups at weeks 4, 8, 12, 24, 36, and 52. Using population-averaged GEE models adjusted for baseline score, age, and sex, the results demonstrated no statistically significant differences between the groups in the magnitude of score changes at any of the predefined follow-up time points (Multimedia Appendix 10).

Discussion

Principal Findings

This multicenter RCT demonstrated that a structured, smartphone-based multimodal digital education program for caregivers, when integrated with standard care, significantly reduced the substantial proportion of early relapses in children aged 0 to 6 years with moderate-to-severe

AD, compared to conventional outpatient consultation alone. This early benefit was further supported by Kaplan-Meier survival analysis showing a clearer separation of relapse-free curves during the early follow-up period. Consistent with the study's primary objective, these results confirm that the digital educational intervention effectively achieved short-term relapse prevention. However, differences in relapse rates appeared to diminish over time, and no notable differences were observed in secondary end points assessing disease severity or quality of life across the 52-week follow-up.

The observed reduction in early relapse aligns with the core principle of AD management, which emphasizes the critical role of effective patient and caregiver education in improving clinical outcomes [8-12]. The success of our digital program likely stems from its multimodal design, which combined frequent, brief multimedia modules with a "Real-Time Clinician Access" pathway ("Green Channel"). This combination probably enhanced caregivers' ability to detect early signs of worsening and initiate prompt interventions, thereby preventing progression to full-blown relapse, even in the absence of measurable changes in objective severity indices. The platform's adherence rate suggested

better engagement compared with what is often observed in traditional formats [33], indicating improved feasibility and user engagement.

Our findings are consistent with prior evidence demonstrating that structured education improves short-term management and adherence in pediatric AD [16-23,34-37]. However, they also highlight a common challenge: achieving long-term disease modulation with brief interventions is difficult. The diminishing effect on relapse prevention after the initial 12 weeks may be attributed to several factors. First, the structured program builds knowledge and habits, but its impact may wane without ongoing reinforcement [38]. Second, the natural relapsing-remitting course of AD may eventually overshadow the effects of a time-limited intervention. Furthermore, despite good initial adherence, participant engagement with digital health interventions often declines over time [39].

A critical component contributing to the early success was the integrated “Real-Time Clinician Access,” used by a notable portion of participants during flares or uncertainty. This feature provided timely guidance, effectively replicating the benefit of rapid in-person intervention during exacerbations without the associated logistical burdens. This mechanism, improved early recognition and intervention facilitated by accessible education and on-demand clinical support, provides a plausible explanation for the significant reduction in early relapse rates, underscoring that the primary value of the intervention lies in optimizing the behavioral and self-management aspects of AD care.

The absence of significant differences in disease severity and QoL scores suggests that while the intervention improved caregivers’ short-term flare management, it did not fundamentally alter the underlying core inflammatory process within the assessed follow-up period. This distinction has practical implications: digital education may be most valuable as a tool to reduce short-term exacerbations and health care utilization, complementing rather than replacing ongoing medical and pharmacological strategies needed to modify underlying disease activity.

Traditional educational formats (face-to-face counseling [34-37], workshops [16-19], and eczema schools [20-23]) are effective but face significant scalability challenges due to their resource-intensive nature, geographical barriers, and time constraints for families and clinicians [35]. Passive educational materials, such as leaflets and videos, are limited by a lack of interactivity and personalization [26,36,37]. Our study addresses these limitations by leveraging widespread smartphone access to deliver a scalable, multimodal intervention. The platform’s use of brief, engaging modules (animated stories, videos, and illustrated texts) delivered 3 times weekly made essential educational topics accessible to caregivers with varying literacy levels and busy schedules.

Limitations

Several limitations must be acknowledged. First, smartphone proficiency was an enrollment requirement, potentially excluding digitally underserved groups (eg, from rural or

socioeconomically disadvantaged backgrounds) and limiting the generalizability of our findings to urban or digitally connected families. Future implementations should consider hybrid delivery models combining digital modules with printed materials or in-person sessions to enhance inclusivity. Second, understanding of the educational materials was not formally assessed, which may influence outcomes. Third, although early retention differed between groups, a considerable number of participants did not complete long-term follow-up, potentially affecting the accuracy of long-term outcome estimates. Fourth, although outcome assessors were blinded, caregivers and clinicians were not, creating potential for performance or reporting bias. Fifth, caregiver demographic variables (eg, age, education, and occupation) were not collected, limiting our ability to explore effect modification by caregiver characteristics. While the exclusion of ‘left-behind children’ and the predominance of parent caregivers likely reduced heterogeneity in living arrangements and direct caregiving availability, unmeasured socioeconomic or educational differences could still influence the uptake and use of digital education. Finally, while the control group also had access to the platform for noneducational purposes (eg, data entry, random allocation, and scheduling visits), they did not receive the structured educational modules or ‘Green Channel’ clinician access. Therefore, the observed effect likely reflects the combined impact of the educational content and the interactive digital delivery modality, rather than platform access alone. Future trials should include comparative arms using alternative digital formats (eg, app-based platforms and interactive chatbots) to disentangle which specific features most strongly influence adherence and relapse outcomes.

Conclusions and Broader Implications

In conclusion, this large multicenter RCT demonstrates that a structured, smartphone-based digital education program for caregivers, featuring interactive modules and real-time clinician support, can significantly reduce early relapse rates in young children with moderate-to-severe AD. This finding indicates that scalable digital education can strengthen short-term relapse prevention by optimizing caregiver empowerment and flare management, a strategy particularly relevant in regions with high smartphone penetration.

The broader implications of our study are 3-fold. First, given the high burden of AD and the scalability of digital tools, such interventions hold promise for improving access to quality education and potentially reducing health care disparities. Second, the lower dropout rate in the intervention group suggests that well-designed digital platforms may improve retention in long-term pediatric dermatology research and care. Finally, the transient nature of the benefit underscores that digital education should be viewed as a complementary adjunct to, not a replacement for, ongoing medical management.

Future research should prioritize (1) developing hybrid models that integrate digital education with targeted in-person support to enhance emotional connection and engagement; (2) designing strategies for sustained engagement, such

as “booster” modules and adaptive content; (3) ensuring digital accessibility for underserved populations to address health equity; (4) conducting rigorous economic evaluations; and (5) conducting head-to-head comparisons of different digital features and mechanistic studies to identify the active ingredients of digital education.

Acknowledgments

The authors sincerely thank Mr. Lei Yan and Ms. Ping Yang for their kind support and assistance in the statistical analysis of the data. The authors declare the use of generative AI in the research and writing process. According to the GAIDeT taxonomy (2025), translation was delegated to GAI tools under full human supervision. The GAI tool used was ChatGPT 5. Responsibility for the final manuscript lies entirely with the authors. GAI tools are not listed as authors and do not bear responsibility for the final outcomes. Declaration submitted by Huan Yang.

Funding

This study was funded by Beijing Medical Award Foundation (2019-1115), the Joint Foundation of Chongqing Municipal Health Commission and Municipal Science and Technology Bureau (2021MSXM203), CQMU Program for Youth Innovation in Future Medicine (W0177), and Children’s Hospital Affiliated to Chongqing Medical University (RC05036). The funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.

Data Availability

The anonymized datasets generated and analyzed during this study are not publicly available due to participant privacy and institutional data protection policy but are available from the corresponding author on reasonable request.

Authors’ Contributions

Conceptualization: HY, HW, LM, XL

Methodology: HY, HW, LM, XL

Investigation: HY, HS, LW, PL, YL, QL, XH, JT, JC, HQ, JP Chen, XD, PW, LD, ZL, WL, YL, LL, SY, YG, LY, XS

Data Curation: HY, HS, LW, PL

Formal Analysis: HY, HS, LW, PL

Resources: HW, XL, HY

Software: HY

Validation: HY, HS, LW, PL

Funding Acquisition: HW, XL, HY

Project Administration: HW, LM, XL

Supervision: HW, LM, XL

Writing-Original Draft: HY

Writing-Review & Editing: HY, HS, LW

Visualization: HY, HS, LW, PL

All authors reviewed and approved the final manuscript and agree to be accountable for all aspects of the work.

Conflicts of Interest

None declared.

Multimedia Appendix 1

List of participating hospitals.

[\[PDF File \(Adobe File\), 67 KB-Multimedia Appendix 1\]](#)

Multimedia Appendix 2

Atopic dermatitis awareness material.

[\[PDF File \(Adobe File\), 78 KB-Multimedia Appendix 2\]](#)

Multimedia Appendix 3

Procedural overview illustrating the standardized workflow for patient enrollment and identity verification within the “Skin Care E-Station” platform, with representative interface screenshots supporting each operational step.

[\[PDF File \(Adobe File\), 295 KB-Multimedia Appendix 3\]](#)

Multimedia Appendix 4

Education action plan.

[\[PDF File \(Adobe File\), 4038 KB-Multimedia Appendix 4\]](#)

Multimedia Appendix 5

Sample illustrated educational text.

[[PNG File \(Portable Network Graphics File\), 538 KB-Multimedia Appendix 5](#)]

Multimedia Appendix 6

Sample caregiver-facing informational images.

[[PNG File \(Portable Network Graphics File\), 295 KB-Multimedia Appendix 6](#)]

Multimedia Appendix 7

Sample video.

[[MP4 File \(MP4 video File\), 15585 KB-Multimedia Appendix 7](#)]

Multimedia Appendix 8

Animated stories.

[[PDF File \(Adobe File\), 122 KB-Multimedia Appendix 8](#)]

Multimedia Appendix 9

SCORAD self-assessment.

[[PDF File \(Adobe File\), 122 KB-Multimedia Appendix 9](#)]

Multimedia Appendix 10

Comparison of changes in disease severity and quality of life scores between 2 groups over time.

[[DOCX File \(Microsoft Word File\), 16 KB-Multimedia Appendix 10](#)]

Checklist 1

CONSORT checklist.

[[PDF File \(Adobe File\), 1122 KB-Checklist 1](#)]

References

1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet*. Aug 1, 2020;396(10247):345-360. [doi: [10.1016/S0140-6736\(20\)31286-1](#)] [Medline: [32738956](#)]
2. Nutten S. Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab*. 2015;66 Suppl 1:8-16. [doi: [10.1159/000370220](#)] [Medline: [25925336](#)]
3. Guo Y, Zhang H, Liu Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1-12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence. *J Eur Acad Dermatol Venereol*. Aug 2019;33(8):1569-1576. [doi: [10.1111/jdv.15618](#)] [Medline: [30989708](#)]
4. Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1–7 ys. *Sci Rep*. 2016;6(1):29751. [doi: [10.1038/srep29751](#)]
5. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. *Dermatol Clin*. Jul 2017;35(3):283-289. [doi: [10.1016/j.det.2017.02.002](#)] [Medline: [28577797](#)]
6. Nicolescu AC, Strilciuc S, Lăpădatu R, Grad DA, Vlădescu C, Olteanu R. The economic burden of atopic dermatitis in Romania: a broad perspective. *Front Public Health*. 2024;12:1531042. [doi: [10.3389/fpubh.2024.1531042](#)] [Medline: [39850862](#)]
7. Girolomoni G, Busà VM. Flare management in atopic dermatitis: from definition to treatment. *Ther Adv Chronic Dis*. Jan 2022;13. [doi: [10.1177/20406223211066728](#)]
8. Lapeere H, Speeckaert R, Baeck M, et al. Belgian atopic dermatitis guidelines. *Acta Clin Belg*. Feb 2024;79(1):62-74. [doi: [10.1080/17843286.2023.2285576](#)] [Medline: [37997950](#)]
9. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. *J Eur Acad Dermatol Venereol*. Nov 2022;36(11):1904-1926. [doi: [10.1111/jdv.18429](#)] [Medline: [36056736](#)]
10. Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021. *J Dermatol*. Oct 2022;49(10):e315-e375. [doi: [10.1111/1346-8138.16527](#)] [Medline: [35996152](#)]
11. Panel A, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. *Ann Allergy Asthma Immunol*. Mar. 2024;132(3):274-312. [doi: [10.1016/j.anai.2023.11.009](#)]
12. Xu Y, Zhi-Qiang S, Wei L, et al. Guidelines for diagnosis and treatment of atopic dermatitis in China. *Int J Derm Venereol*. 2021;4(1):1-9. [doi: [10.1097/JD9.000000000000143](#)]

13. Greenwell K, Sivyer K, Howells L, et al. "Eczema shouldn't control you; you should control eczema": qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema. *Br J Dermatol*. Mar 30, 2023;188(4):506-513. [doi: [10.1093/bjd/ljac115](https://doi.org/10.1093/bjd/ljac115)] [Medline: [36745562](https://pubmed.ncbi.nlm.nih.gov/36745562/)]
14. Andrade LF, Abdi P, Mashoudy KD, et al. Effectiveness of atopic dermatitis patient education programs - a systematic review and meta-analysis. *Arch Dermatol Res*. Apr 25, 2024;316(5):135. [doi: [10.1007/s00403-024-02871-y](https://doi.org/10.1007/s00403-024-02871-y)] [Medline: [38662127](https://pubmed.ncbi.nlm.nih.gov/38662127/)]
15. Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. *Ann Allergy Asthma Immunol*. Sep 2021;127(3):293-300. [doi: [10.1016/j.anai.2021.04.036](https://doi.org/10.1016/j.anai.2021.04.036)] [Medline: [33971364](https://pubmed.ncbi.nlm.nih.gov/33971364/)]
16. Moore EJ, Williams A, Manias E, Varigos G, Donath S. Eczema workshops reduce severity of childhood atopic eczema. *Australas J Dermatol*. May 2009;50(2):100-106. [doi: [10.1111/j.1440-0960.2009.00515.x](https://doi.org/10.1111/j.1440-0960.2009.00515.x)] [Medline: [19397561](https://pubmed.ncbi.nlm.nih.gov/19397561/)]
17. Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. *J Allergy Clin Immunol*. Sep 2017;140(3):845-853. [doi: [10.1016/j.jaci.2017.01.029](https://doi.org/10.1016/j.jaci.2017.01.029)] [Medline: [28242304](https://pubmed.ncbi.nlm.nih.gov/28242304/)]
18. Kupfer J, Gieler U, Diepgen TL, et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. *J Psychosom Res*. Apr 2010;68(4):353-358. [doi: [10.1016/j.jpsychores.2009.04.014](https://doi.org/10.1016/j.jpsychores.2009.04.014)] [Medline: [20307702](https://pubmed.ncbi.nlm.nih.gov/20307702/)]
19. Liang Y, Tian J, Shen CP, et al. Therapeutic patient education in children with moderate to severe atopic dermatitis: a multicenter randomized controlled trial in China. *Pediatr Dermatol*. Jan 2018;35(1):70-75. [doi: [10.1111/pde.13362](https://doi.org/10.1111/pde.13362)] [Medline: [29243849](https://pubmed.ncbi.nlm.nih.gov/29243849/)]
20. Grossman SK, Schut C, Kupfer J, Valdes-Rodriguez R, Gieler U, Yosipovitch G. Experiences with the first eczema school in the United States. *Clin Dermatol*. 2018;36(5):662-667. [doi: [10.1016/j.clindermatol.2018.05.006](https://doi.org/10.1016/j.clindermatol.2018.05.006)] [Medline: [30217280](https://pubmed.ncbi.nlm.nih.gov/30217280/)]
21. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ*. Apr 22, 2006;332(7547):933-938. [doi: [10.1136/bmj.332.7547.933](https://doi.org/10.1136/bmj.332.7547.933)] [Medline: [16627509](https://pubmed.ncbi.nlm.nih.gov/16627509/)]
22. Broberg A, Kalimo K, Lindblad B, Swanbeck G. Parental education in the treatment of childhood atopic eczema. *Acta Derm Venereol*. 1990;70(6):495-499. [Medline: [1981422](https://pubmed.ncbi.nlm.nih.gov/1981422/)]
23. Futamura M, Ito K, Otsuji K, et al. Effects of "Skin Care School," a parental education program on childhood atopic dermatitis conducted during short hospitalization stays. *Arerugi*. Dec 2009;58(12):1610-1618. [Medline: [20220302](https://pubmed.ncbi.nlm.nih.gov/20220302/)]
24. LeBovidge JS, Timmons K, Delano S, et al. Improving patient education for atopic dermatitis: a randomized controlled trial of a caregiver handbook. *Pediatr Dermatol*. Mar 2021;38(2):396-404. [doi: [10.1111/pde.14519](https://doi.org/10.1111/pde.14519)] [Medline: [33486817](https://pubmed.ncbi.nlm.nih.gov/33486817/)]
25. Park GY, Park H sun, Cho S, Yoon HS. The effectiveness of tailored education on the usage of moisturizers in atopic dermatitis: a pilot study. *Ann Dermatol*. 2017;29(3):360. [doi: [10.5021/ad.2017.29.3.360](https://doi.org/10.5021/ad.2017.29.3.360)]
26. Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol*. Mar 2011;64(3):502-507. [doi: [10.1016/j.jaad.2010.01.051](https://doi.org/10.1016/j.jaad.2010.01.051)] [Medline: [21236514](https://pubmed.ncbi.nlm.nih.gov/21236514/)]
27. Tier HL, Balogh EA, Bashyam AM, et al. Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review. *Dermatol Ther (Heidelb)*. Apr 2021;11(2):415-431. [doi: [10.1007/s13555-021-00500-4](https://doi.org/10.1007/s13555-021-00500-4)] [Medline: [33599887](https://pubmed.ncbi.nlm.nih.gov/33599887/)]
28. Patel N, Feldman SR. Adherence in atopic dermatitis. *Adv Exp Med Biol*. 2017;1027:139-159. [doi: [10.1007/978-3-319-64804-0_12](https://doi.org/10.1007/978-3-319-64804-0_12)] [Medline: [29063437](https://pubmed.ncbi.nlm.nih.gov/29063437/)]
29. Wilken B, Zaman M, Asai Y. Patient education in atopic dermatitis: a scoping review. *Allergy Asthma Clin Immunol*. Oct 13, 2023;19(1):89. [doi: [10.1186/s13223-023-00844-w](https://doi.org/10.1186/s13223-023-00844-w)] [Medline: [37833754](https://pubmed.ncbi.nlm.nih.gov/37833754/)]
30. Golinelli D, Boetto E, Carullo G, Nuzzolese AG, Landini MP, Fantini MP. Adoption of digital technologies in health care during the COVID-19 pandemic: systematic review of early scientific literature. *J Med Internet Res*. Nov 6, 2020;22(11):e22280. [doi: [10.2196/22280](https://doi.org/10.2196/22280)] [Medline: [33079693](https://pubmed.ncbi.nlm.nih.gov/33079693/)]
31. Yuan L, Lingling L, Shan W, et al. Efficacy and safety of 0.03% tacrolimus ointment in the long-term intermittent maintenance treatment of atopic dermatitis in children: a multicenter randomized controlled clinical trial. *Chin J Dermatol*. 2019;52(8):519-524. [doi: [10.3760/cma.j.issn.0412-4030.2019.08.001](https://doi.org/10.3760/cma.j.issn.0412-4030.2019.08.001)] [Medline: [30656725](https://pubmed.ncbi.nlm.nih.gov/30656725/)]
32. Overall JE, Shobaki G, Shivakumar C, Steele J. Adjusting sample size for anticipated dropouts in clinical trials. *Psychopharmacol Bull*. 1998;34(1):25-33. [Medline: [9564195](https://pubmed.ncbi.nlm.nih.gov/9564195/)]
33. Bass AM, Anderson KL, Feldman SR. Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. *J Clin Med*. Jan 27, 2015;4(2):231-242. [doi: [10.3390/jcm4020231](https://doi.org/10.3390/jcm4020231)] [Medline: [26239125](https://pubmed.ncbi.nlm.nih.gov/26239125/)]

34. Barbarot S, Aubert H, Vibet MA, et al. Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial. *Br J Dermatol*. Jul 16, 2024;191(2):177-186. [doi: [10.1093/bjd/ljae111](https://doi.org/10.1093/bjd/ljae111)] [Medline: [38863109](https://pubmed.ncbi.nlm.nih.gov/38863109/)]
35. Cheong JYV, Hie SL, Koh EW, de Souza NNA, Koh MJA. Impact of pharmacists' counseling on caregiver's knowledge in the management of pediatric atopic dermatitis. *Pediatr Dermatol*. Jan 2019;36(1):105-109. [doi: [10.1111/pde.13708](https://doi.org/10.1111/pde.13708)] [Medline: [30408232](https://pubmed.ncbi.nlm.nih.gov/30408232/)]
36. Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. *Br J Dermatol*. Mar 2002;146(3):432-439. [doi: [10.1046/j.1365-2133.2002.04603.x](https://doi.org/10.1046/j.1365-2133.2002.04603.x)] [Medline: [11952543](https://pubmed.ncbi.nlm.nih.gov/11952543/)]
37. Rolinck-Werninghaus C, Trentmann M, Reich A, Lehmann C, Staab D. Improved management of childhood atopic dermatitis after individually tailored nurse consultations: a pilot study. *Pediatr Allergy Immunol*. Dec 2015;26(8):805-810. [doi: [10.1111/pai.12338](https://doi.org/10.1111/pai.12338)] [Medline: [25643831](https://pubmed.ncbi.nlm.nih.gov/25643831/)]
38. Boswell JF, Kraus DR, Miller SD, Lambert MJ. Implementing routine outcome monitoring in clinical practice: benefits, challenges, and solutions. *Psychother Res*. 2015;25(1):6-19. [doi: [10.1080/10503307.2013.817696](https://doi.org/10.1080/10503307.2013.817696)] [Medline: [23885809](https://pubmed.ncbi.nlm.nih.gov/23885809/)]
39. Cross SP, Alvarez-Jimenez M. The digital cumulative complexity model: a framework for improving engagement in digital mental health interventions. *Front Psychiatry*. 2024;15:1382726. [doi: [10.3389/fpsy.2024.1382726](https://doi.org/10.3389/fpsy.2024.1382726)] [Medline: [39290300](https://pubmed.ncbi.nlm.nih.gov/39290300/)]

Abbreviations

AD: atopic dermatitis
CDLQI: Children's Dermatology Life Quality Index
CONSORT: Consolidated Standards of Reporting Trials
CRO: Clinical Research Organization
DFI: Dermatitis Family Impact
EAP: education action plan
HR: hazard ratio
IDQOL: Infant's Dermatitis Quality of Life Index
IGA: Investigator's Global Assessment
ITT: intention-to-treat
MICE: multiple imputation by chained equation
POEM: Patient-Oriented Eczema Measure
PP-NRS: Peak Pruritus Numerical Rating Scale
QoL: quality of life
RCT: randomized controlled trial
RR: relative risk
SCORAD: Scoring Atopic Dermatitis

Edited by Naomi Cahill; peer-reviewed by Xiaolong Liang, Yutong Zhang; submitted 24.Jun.2025; final revised version received 14.Nov.2025; accepted 18.Nov.2025; published 07.Jan.2026

Please cite as:

Yang H, Shu H, Wang LH, Li P, Li YL, Li QF, Han XP, Tian J, Chang J, Qian H, Chen JP, Ding XQ, Wu PQ, Dou LM, Luo Z, Li W, Lin YY, Li L, Yue SZ, Gu Y, Yang L, Sun XH, Luo XY, Ma L, Wang H

Smartphone-Based Digital Eczema Education Program for Atopic Dermatitis in Children Aged 0 to 6 Years: Multicenter, Randomized, Parallel Controlled Clinical Study

J Med Internet Res 2026;28:e79559

URL: <https://www.jmir.org/2026/1/e79559>

doi: [10.2196/79559](https://doi.org/10.2196/79559)

© Huan Yang, Hong Shu, Liu-hui Wang, Ping Li, Yun-ling Li, Qin-feng Li, Xiu-ping Han, Jing Tian, Jing Chang, Hua Qian, Jing-ping Chen, Xin-qiang Ding, Pan-qian Wu, Li-min Dou, Zhen Luo, Wei Li, Yang-yang Lin, Lin Li, Shu-zhen Yue, Yang Gu, Li Yang, Xiao-hong Sun, Xiao-yan Luo, Lin Ma, Hua Wang. Originally published in the Journal of Medical Internet Research (<https://www.jmir.org>), 07.Jan.2026. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research

(ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on <https://www.jmir.org/>, as well as this copyright and license information must be included.